Genetic Alterations in Differentiated Thyroid Cancer Patients with Acromegaly

Experimental and Clinical Endocrinology and Diabetes

Volumn 124, Issue 3, 2016, Pages 198-202

  Aydin, K ^a   Aydin, C ^a   Dagdelen, S ^a   Tezel, G G ^a   Erbas, T ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

acromegaly; BRAF; genetic alteration; NRAS; thyroid cancer

Indexed keywords

ACROMEGALY; ADULT; ARTICLE; BRAF GENE; CANCER RECURRENCE; CLINICAL ARTICLE; CODON; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; FEMALE; GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LOCAL METASTASIS; MALE; MIDDLE AGED; NRAS GENE; ONCOGENE RAS; ONCOGENE RET; PAX8 GENE; PPAR GAMMA GENE; PRIORITY JOURNAL; CONTROLLED STUDY; GENETICS; MUTATION; RANDOMIZED CONTROLLED TRIAL; THYROID TUMOR;

B RAF KINASE; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ACROMEGALY; ADULT; FEMALE; GENE REARRANGEMENT; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84947800492     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0035-1565061     Document Type: Article

References (39)

1. Orme S. M., McNally R. J., Cartwright R. A. et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab: 1998; 83 2730 2734
2. Baris D., Gridley G., Ron E. et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control: 2002; 13 395 400
3. Wuster C., Steger G., Schmelzle A. et al. Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with acromegaly. Horm Metab Res: 1991; 23 131 134
4. Gullu B. E., Celik O., Gazioglu N. et al. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary: 2010; 13 242 248
5. Tita P., Ambrosio M. R., Scollo C. et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf): 2005; 63 161 167
6. dos Santos M. C., Nascimento G. C., Nascimento A. G. et al. Thyroid cancer in patients with acromegaly: a case-control study. Pituitary: 2013; 16 109 114
7. Dagdelen S., Cinar N., Erbas T. Increased thyroid cancer risk in acromegaly. Pituitary: 2014; 17 299 306
8. Renehan A. G., Brennan B. M. Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab: 2008; 22 639 657
9. Prisco M., Romano G., Peruzzi F. et al. Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res: 1999; 31 80 89
10. Remacle-Bonnet M. M., Garrouste F. L., Heller S. et al. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res: 2000; 60 2007 2017
11. Chen W., Wang S., Tian T. et al. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet: 2009; 17 1668 1675
12. Tode B., Serio M., Rotella C. M. et al. Insulin-like growth factor-I: autocrine secretion by human thyroid follicular cells in primary culture. J Clin Endocrinol Metab: 1989; 69 639 647
13. Roger P., Taton M., Van Sande J. et al. Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab: 1988; 66 1158 1165
14. Derwahl M., Broecker M., Kraiem Z. Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab: 1999; 84 829 834
15. Yashiro T., Ohba Y., Murakami H. et al. Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. Acta Endocrinol (Copenh): 1989; 121 112 120
16. Siegel G., Tomer Y. Is there an association between acromegaly and thyroid carcinoma? A critical review of the literature. Endocr Res: 2005; 31 51 58
17. Hsiao S. J., Nikiforov Y. Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer: 2014; 21 301 313
18. Katznelson L., Laws E. R., Melmed S. et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab: 2014; 99 3933 3951
19. Wan P. T., Garnett M. J., Roe S. M. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell: 2004; 116 855 867
20. Knauf J. A., Ma X., Smith E. P. et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer research: 2005; 65 4238 4245
21. Nikiforova M. N., Lynch R. A., Biddinger P. W. et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab: 2003; 88 2318 2326
22. Nikiforova M. N., Nikiforov Y. E. Molecular diagnostics and predictors in thyroid cancer. Thyroid: 2009; 19 1351 1361
23. Witt R. L., Ferris R. L., Pribitkin E. A. et al. Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope: 2013; 123 1059 1064
24. Nikiforov Y. E. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med: 2011; 135 569 577
25. Kroll T. G., Sarraf P., Pecciarini L. et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science: 2000; 289 1357 1360
26. Bayram F., Gedik V. T., Demir O. et al. Epidemiologic survey: reference ranges of serum insulin-like growth factor 1 levels in Caucasian adult population with immunoradiometric assay. Endocrine: 2011; 40 304 309
27. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer: 2005; 12 245 262
28. Nikiforova M. N., Kimura E. T., Gandhi M. et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab: 2003; 88 5399 5404
29. Kim K. H., Kang D. W., Kim S. H. et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J: 2004; 45 818 821
30. Rivera M., Ricarte-Filho J., Knauf J. et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol: 2010; 23 1191 1200
31. Kim H. K., Lee J. S., Park M. H. et al. Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly. PLoS One: 2014; 9 e110241
32. Mian C., Ceccato F., Barollo S. et al. AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. PLoS One: 2014; 9 e101560
33. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev: 2007; 28 742 762
34. Kim T. H., Park Y. J., Lim J. A. et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer: 2012; 118 1764 1773
35. Lee J. H., Lee E. S., Kim Y. S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer: 2007; 110 38 46
36. Gouveia C., Can N. T., Bostrom A. et al. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg: 2013; 139 1164 1170
37. Tufano R. P., Teixeira G. V., Bishop J. et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine: 2012; 91 274 286
38. Adeniran A. J., Zhu Z., Gandhi M. et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol: 2006; 30 216 222
39. Jung C. K., Little M. P., Lubin J. H. et al. The increase in thyroid cancer incidence during the last 4 decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab: 2014; 99 276 285